Latest Press Release on obesity

Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 24 -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement ...

---

Interim Data from a Clinical Trial Evaluating GI Dynamics’ EndoBarrier™ Gastrointestinal Liner in Patients with Type 2 Diabetes Presented at GASTRO 2009
LEXINGTON, Mass. - GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that interim data from its ongoing clinical study of the EndoBarrier™ Gastrointestinal Liner in obese patients with type 2 diabetes will be presented by Edua

---

Four Senior Executives Join Orexigen(R) Therapeutics Management Team
SAN DIEGO, Calif., Nov. 23 -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management team that is driving the development of its obesity franchise. Additions to t...

---

NACDD Applauds CDC Report for Providing First-Ever County-Level Snapshots of U.S. Obesity Rates
CDC Morbidity and Mortality Weekly Report Also Updates Diabetes County-Level Estimates. The National Association of Chronic Disease Directors (NACDD) applauds the Centers for Disease Control and Prevention (CDC) for releasing estimates that provide the first county-level snapshots of obesity...

---

EnteroMedics Receives Notice of NASDAQ Listing Deficiencies
ST. PAUL, Minn. - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that on November 13, 2009 it received two Nasdaq Staff Deficiency Letters indicating that, for 30 consecu

---